Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cempra Inc (CEMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 147,028
  • Shares Outstanding, K 52,510
  • Annual Sales, $ 18,020 K
  • Annual Income, $ -117,960 K
  • 36-Month Beta 1.12
  • Price/Sales 8.45
  • Price/Cash Flow 0.00
  • Price/Book 1.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +3.70%
on 10/20/17
3.50 -20.00%
on 09/27/17
-0.35 (-11.11%)
since 09/20/17
3-Month
2.60 +7.69%
on 08/28/17
4.50 -37.78%
on 07/24/17
-1.30 (-31.71%)
since 07/20/17
52-Week
2.55 +9.80%
on 12/29/16
24.48 -88.56%
on 10/24/16
-20.68 (-88.07%)
since 10/20/16

Most Recent Stories

More News
Hercules Capital Provides Interim Portfolio Update for Q3 2017

--Closed total new debt and equity commitments of ~$154.0 million to seven (7) companies including five (5) new and two (2) existing portfolio companies in Q3 2017 Closed total new debt and equity commitments...

AVEO : 3.18 (+0.32%)
HTGC : 12.71 (+0.71%)
CEMP : 2.80 (-3.45%)
HTGX : 25.22 (+0.16%)
INSM : 27.55 (+2.11%)
Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment...

CEMP : 2.80 (-3.45%)
Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges

Nabriva Therapeutics' (NBRV) lefamulin shows non-inferiority to Avelox in a phase III study on community-acquired bacterial pneumonia patients.

BAYRY : 34.8000 (-1.16%)
CEMP : 2.80 (-3.45%)
NBRV : 6.33 (-4.67%)
PRTK : 23.20 (-0.22%)
Cempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment...

CEMP : 2.80 (-3.45%)
Malin Investee Company - Melinta Therapeutics - To Be Transformed into a NASDAQ Listed Company

--Definitive agreement entered into with Cempra, Inc.

CEMP : 2.80 (-3.45%)
Cempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company

--Broad pipeline and resources provide multiple opportunities to drive long-term value creation--

CEMP : 2.80 (-3.45%)
Investor Network: Cempra, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Cempra, Inc. (NASDAQ: CEMP) will be discussing their earnings results in their Q2 Earnings Call to be held August 9, 2017 at 8:45 AM Eastern Time.

CEMP : 2.80 (-3.45%)
Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that...

CEMP : 2.80 (-3.45%)
Cempra to Present at the Jefferies 2017 Global Healthcare Conference

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the...

CEMP : 2.80 (-3.45%)
Cempra Presents Data on Ophthalmic Solithromycin at ARVO

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the...

CEMP : 2.80 (-3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance....

See More

Support & Resistance

2nd Resistance Point 3.00
1st Resistance Point 2.90
Last Price 2.80
1st Support Level 2.70
2nd Support Level 2.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart